New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:15 EDTQCORQuestcor continues lower as FDA says reviewing Acthar lab test results
Shares of Questcor (QCOR) are down 3.8% in pre-market trading to $64.90 after falling 9% yesterday following Citron Research claiming the company's Acthar drug faces "severe risk" of being pulled from the market by the FDA. Following the Citron report, the FDA stated in an e-mail to Bloomberg that it had received a letter and lab results from an attorney as mentioned by Citron and was reviewing the materials. Questcor's COO Steve Cartt stated in an e-mail to Bloomberg First Word that "each Acthar lot meets FDA-mandated specifications which have not changed over several decades," the news service reported.
News For QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for QCOR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use